# Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers

> **NCT01843725** · PHASE1 · COMPLETED · sponsor: **Jules Bordet Institute** · enrollment: 37 (actual)

## Conditions studied

- Metastatic Colorectal Cancers
- Metastatic Gastric Cancers
- Metastatic Oesophageal Cancers
- Metastatic Pancreatic Cancers
- Metastatic Biliary Cancers
- Metastatic Breast Cancers

## Interventions

- **DRUG:** capecitabine
- **DRUG:** aflibercept
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT01843725
- **Lead sponsor:** Jules Bordet Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2018-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01843725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01843725, "Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01843725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*